RBC Capital analyst Kennen MacKay lowered his price target on Athenex to $29 after it Q4 earnings miss, saying the termination of its KX-391 China partnership kept it from achieving a $14.5M revenue milestone. The analyst is keeping his Outperform rating on the shares however, noting that the company's "API/specialty-pharma business is continuing to execute ahead of mid-2019 phase 3 Oraxol data".
https://thefly.com/landingPageNews.php?id=2877863
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.